Our study further demonstrated that low circulating sCD40L levels in HCC patients early during SBRT are associated with increased liver toxicity and that low sCD40L levels at baseline are associated with increased risk of death at 3 months post SBRT. Here, CD40LG is linked to hepatocellular carcinoma.